<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H — News on 6ix</title>
<link>https://6ix.com/company/sichuan-kelun-biotech</link>
<description>Latest news and press releases for Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 13 May 2026 00:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/sichuan-kelun-biotech" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68368ced78dffbe2df16d1d6.webp</url>
<title>Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H</title>
<link>https://6ix.com/company/sichuan-kelun-biotech</link>
</image>
<item>
<title>Kelun-Biotech Receives Investigational New Drug Approval from CDE for SKB118, a PD-1 x VEGF Bispecific Antibody</title>
<link>https://6ix.com/company/sichuan-kelun-biotech/news/kelun-biotech-receives-investigational-new-drug-approval-from-cde-for-skb118-a-pd-1-x-vegf-bispecific-antibody</link>
<guid isPermaLink="true">https://6ix.com/company/sichuan-kelun-biotech/news/kelun-biotech-receives-investigational-new-drug-approval-from-cde-for-skb118-a-pd-1-x-vegf-bispecific-antibody</guid>
<pubDate>Wed, 13 May 2026 00:00:00 GMT</pubDate>
<description>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that it has received a clinical trial notice from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) approving the Investigational New Drug (IND) application for PD-1 x VEGF bispecific antibody SKB118 (also known as CR-001) for the treatment of advanced solid tumors.</description>
</item>
<item>
<title>The sNDA for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First‑Line Treatment for PD-L1-positive NSCLC Accepted for Review by NMPA</title>
<link>https://6ix.com/company/sichuan-kelun-biotech/news/the-snda-for-sacituzumab-tirumotecan-sac-tmt-in-combination-with-pembrolizumab-as-firstline-treatment-for-pd-l1-positive-nsclc-accepted-for-review-by-nmpa</link>
<guid isPermaLink="true">https://6ix.com/company/sichuan-kelun-biotech/news/the-snda-for-sacituzumab-tirumotecan-sac-tmt-in-combination-with-pembrolizumab-as-firstline-treatment-for-pd-l1-positive-nsclc-accepted-for-review-by-nmpa</guid>
<pubDate>Fri, 08 May 2026 11:29:00 GMT</pubDate>
<description>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company") announced that the sNDA (the "Application") for the Company's TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®) was accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China. The application is for sac-TMT in combination with MSD's[1] anti-PD-1 monoclonal antibody pembrolizumab (KEYTRUDA®[2]) as first‑line treatment</description>
</item>
<item>
<title>Kelun-Biotech Announces Three Clinical Study Results Selected for Oral Presentations at 2026 ASCO Annual Meeting</title>
<link>https://6ix.com/company/sichuan-kelun-biotech/news/kelun-biotech-announces-three-clinical-study-results-selected-for-oral-presentations-at-2026-asco-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/sichuan-kelun-biotech/news/kelun-biotech-announces-three-clinical-study-results-selected-for-oral-presentations-at-2026-asco-annual-meeting</guid>
<pubDate>Wed, 22 Apr 2026 00:59:00 GMT</pubDate>
<description>The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago from May 29 to June 2. In this meeting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) will present results from three clinical studies, including data from its TROP2 ADC sacituzumab tirumotecan (sac-TMT, 佳泰莱®), next-generation selective RET inhibitor lunbotinib fumarate (A400/EP0031, 宁泰莱®[1]) and novel ADC SKB500. The abstracts for these studies will be published on the ASCO official websit</description>
</item>
<item>
<title>Kelun-Biotech Announces Results from the SKB264-II-06/MK-2870-002 Study of Sacituzumab Tirumotecan (Sac-TMT) in Gynecologic Oncology Presented at 2026 SGO</title>
<link>https://6ix.com/company/sichuan-kelun-biotech/news/kelun-biotech-announces-results-from-the-skb264-ii-06mk-2870-002-study-of-sacituzumab-tirumotecan-sac-tmt-in-gynecologic-oncology-presented-at-2026-sgo</link>
<guid isPermaLink="true">https://6ix.com/company/sichuan-kelun-biotech/news/kelun-biotech-announces-results-from-the-skb264-ii-06mk-2870-002-study-of-sacituzumab-tirumotecan-sac-tmt-in-gynecologic-oncology-presented-at-2026-sgo</guid>
<pubDate>Tue, 14 Apr 2026 00:00:00 GMT</pubDate>
<description>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that results from both the ovarian cancer cohort and the cervical cancer cohort of Phase II study SKB264-II-06/MK-2870-002 of the TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®), in combination with MSD's[1] anti-PD-1 monoclonal antibody pembrolizumab (KEYTRUDA®[2]), were selected for oral presentation at the 2026 Society of Gynecologic Oncology (SGO) Annual Me</description>
</item>
<item>
<title>Kelun-Biotech Approved by HKEX to Remove "B" Marker from Stock Code, Representing a New Stage of Development</title>
<link>https://6ix.com/company/sichuan-kelun-biotech/news/kelun-biotech-approved-by-hkex-to-remove-b-marker-from-stock-code-representing-a-new-stage-of-development</link>
<guid isPermaLink="true">https://6ix.com/company/sichuan-kelun-biotech/news/kelun-biotech-approved-by-hkex-to-remove-b-marker-from-stock-code-representing-a-new-stage-of-development</guid>
<pubDate>Thu, 09 Apr 2026 10:33:00 GMT</pubDate>
<description>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) today announced that following an application to The Stock Exchange of Hong Kong Limited (the "Stock Exchange") pursuant to Rule 18A.12 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules"), the Stock Exchange has approved the dis-application of Rules 18A.09 to 18A.11 of the Listing Rules to the Company. As the Company has satisfied the relevan</description>
</item>
<item>
<title>Kelun-Biotech Receives IND Approval for SKB103, a Novel TAA-PD-L1 Bispecific ADC</title>
<link>https://6ix.com/company/sichuan-kelun-biotech/news/kelun-biotech-receives-ind-approval-for-skb103-a-novel-taa-pd-l1-bispecific-adc</link>
<guid isPermaLink="true">https://6ix.com/company/sichuan-kelun-biotech/news/kelun-biotech-receives-ind-approval-for-skb103-a-novel-taa-pd-l1-bispecific-adc</guid>
<pubDate>Tue, 24 Mar 2026 09:24:00 GMT</pubDate>
<description>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) today announced that the Investigational New Drug (IND) application for SKB103, its self-developed novel bispecific antibody-drug conjugate with combined Tumor-Associated Antigen-targeting and Immuno-Oncology mechanisms (TAA-PD-L1 bsADC), has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the treatment of advanced solid tumors. T</description>
</item>
<item>
<title>KELUN-BIOTECH ANNOUNCED 2025 ANNUAL RESULTS: MULTIPLE PRODUCTS SUCCESSFULLY LAUNCHED WITH TIERED PIPELINE READY FOR TAKE-OFF</title>
<link>https://6ix.com/company/sichuan-kelun-biotech/news/kelun-biotech-announced-2025-annual-results-multiple-products-successfully-launched-with-tiered-pipeline-ready-for-take-off</link>
<guid isPermaLink="true">https://6ix.com/company/sichuan-kelun-biotech/news/kelun-biotech-announced-2025-annual-results-multiple-products-successfully-launched-with-tiered-pipeline-ready-for-take-off</guid>
<pubDate>Tue, 24 Mar 2026 02:44:00 GMT</pubDate>
<description>Sichuan Kelun-Biotech Pharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", Stock Code: 6990.HK) announced its audited consolidated results for the year ended 31 December 2025 (the "Reporting Period").</description>
</item>
<item>
<title>Harbour BioMed Reports the Online Publication of Phase I Results for HBM9378 (SKB378/WIN378), a TSLP-Targeting Antibody</title>
<link>https://6ix.com/company/sichuan-kelun-biotech/news/harbour-biomed-reports-the-online-publication-of-phase-i-results-for-hbm9378-skb378win378-a-tslp-targeting-antibody</link>
<guid isPermaLink="true">https://6ix.com/company/sichuan-kelun-biotech/news/harbour-biomed-reports-the-online-publication-of-phase-i-results-for-hbm9378-skb378win378-a-tslp-targeting-antibody</guid>
<pubDate>Mon, 23 Mar 2026 03:14:00 GMT</pubDate>
<description>Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics focusing on immunology and immune-oncology, today announced the online publication of the first-in-human Phase I trial (NCT05790694/CTR20221961) of HBM9378 (also known as SKB378 or WIN378), led by Dr. Min Xu, Physician in Respiratory Medicine at Chengdu Fifth People's Hospital, in the peer-reviewed journal Drug Design, Development and Therapy.</description>
</item>
<item>
<title>Kelun-Biotech to Present the Final OS Analysis of Sacituzumab Tirumotecan (Sac-TMT) from the OptiTROP-Lung03 Study</title>
<link>https://6ix.com/company/sichuan-kelun-biotech/news/kelun-biotech-to-present-the-final-os-analysis-of-sacituzumab-tirumotecan-sac-tmt-from-the-optitrop-lung03-study</link>
<guid isPermaLink="true">https://6ix.com/company/sichuan-kelun-biotech/news/kelun-biotech-to-present-the-final-os-analysis-of-sacituzumab-tirumotecan-sac-tmt-from-the-optitrop-lung03-study</guid>
<pubDate>Wed, 18 Mar 2026 14:31:00 GMT</pubDate>
<description>The 2026 European Lung Cancer Congress (ELCC) will be held in Copenhagen, Denmark, from March 25 to 28, 2026 (local time). At this congress, the final OS analysis from the pivotal study (OptiTROP-Lung03) of sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®), a TROP2 ADC developed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK), has been selected as a Late-Breaking Abstract (LBA) (Presentation Number: LBA4). Professor Yunpeng Ya</description>
</item>
<item>
<title>Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Atopic Dermatitis</title>
<link>https://6ix.com/company/sichuan-kelun-biotech/news/kelun-biotech-and-harbour-biomed-announce-nmpa-approval-of-ind-application-for-skb575hbm7575-for-the-treatment-of-atopic-dermatitis</link>
<guid isPermaLink="true">https://6ix.com/company/sichuan-kelun-biotech/news/kelun-biotech-and-harbour-biomed-announce-nmpa-approval-of-ind-application-for-skb575hbm7575-for-the-treatment-of-atopic-dermatitis</guid>
<pubDate>Mon, 09 Mar 2026 11:38:00 GMT</pubDate>
<description>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) and Harbour BioMed (HKEX: 02142) today announced that the National Medical Products Administration (NMPA) of China has approved the Investigational New Drug (IND) application for SKB575/HBM7575, a long-acting bispecific antibody targeting thymic stromal lymphopoietin (TSLP) and an undisclosed target co-developed by the two parties, for the treatment of atopic dermatitis.</description>
</item>
<item>
<title>Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/sichuan-kelun-biotech/news/crescent-biopharma-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-highlights-1</link>
<guid isPermaLink="true">https://6ix.com/company/sichuan-kelun-biotech/news/crescent-biopharma-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-highlights-1</guid>
<pubDate>Thu, 26 Feb 2026 12:30:00 GMT</pubDate>
<description>Established partnership with Kelun-Biotech expanding pipeline and accelerating combination strategy with CR-001, PD-1 x VEGF bispecific antibody, and multiple ADCs ASCEND Phase 1/2 global clinical trial underway to evaluate CR-001 in advanced solid tumors with three additional clinical trials across the portfolio expected to initiate in 2026 Completed $185 million private placement, supporting several key clinical data readouts beginning in Q1 2027 and providing expected cash runway into 2028 WA</description>
</item>
<item>
<title>Kelun-Biotech Announces Fourth Indication for Sacituzumab Tirumotecan (sac-TMT) Approved by NMPA in HR+/HER2- Breast Cancer</title>
<link>https://6ix.com/company/sichuan-kelun-biotech/news/kelun-biotech-announces-fourth-indication-for-sacituzumab-tirumotecan-sac-tmt-approved-by-nmpa-in-hrher2-breast-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/sichuan-kelun-biotech/news/kelun-biotech-announces-fourth-indication-for-sacituzumab-tirumotecan-sac-tmt-approved-by-nmpa-in-hrher2-breast-cancer</guid>
<pubDate>Fri, 06 Feb 2026 09:00:00 GMT</pubDate>
<description>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that a new indication application for its TROP2-directed ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®) has been approved by the National Medical Products Administration (NMPA) of China for treatment of adult patients with unresectable or metastatic HR+/HER2- (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer (BC) who have received prior endocrine therapy (ET) and at leas</description>
</item>
<item>
<title>Kelun-Biotech Showcases Innovative Achievements and Future Development Strategy at the 44th Annual JPM Healthcare Conference</title>
<link>https://6ix.com/company/sichuan-kelun-biotech/news/kelun-biotech-showcases-innovative-achievements-and-future-development-strategy-at-the-44th-annual-jpm-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/sichuan-kelun-biotech/news/kelun-biotech-showcases-innovative-achievements-and-future-development-strategy-at-the-44th-annual-jpm-healthcare-conference</guid>
<pubDate>Thu, 15 Jan 2026 18:30:00 GMT</pubDate>
<description>From January 12 to 15, 2026, the 44th J.P. Morgan Healthcare Conference (JPMHC) was held in San Francisco, California, USA. Dr. Ge Michael, President and CEO of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK), was invited to attend the conference and delivered a keynote speech on the morning of January 15 (local time) and presented the Company's latest achievements in drug R&D, commercialization, and globalization, and outlined its innovation strateg</description>
</item>
<item>
<title>Kelun-Biotech to Attend the 44th J.P. Morgan Healthcare Conference, Sharing Its Business Progresses and Innovation Strategies</title>
<link>https://6ix.com/company/sichuan-kelun-biotech/news/kelun-biotech-attend-44th-j-024400549</link>
<guid isPermaLink="true">https://6ix.com/company/sichuan-kelun-biotech/news/kelun-biotech-attend-44th-j-024400549</guid>
<pubDate>Wed, 07 Jan 2026 02:44:00 GMT</pubDate>
<description>The 44th J.P. Morgan Healthcare Conference (JPMHC) will be held in San Francisco, California, USA, from January 12 to 15, 2026. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) has been invited to attend the conference and Dr. Michael Ge, President and CEO of Kelun-Biotech, will share the company's latest business progresses as well as its innovation capabilities and strategies.</description>
</item>
<item>
<title>Kelun-Biotech Receives Investigational New Drug Approval for ITGB6-Targeted ADC SKB105 from the NMPA</title>
<link>https://6ix.com/company/sichuan-kelun-biotech/news/kelun-biotech-receives-investigational-new-drug-approval-for-itgb6-targeted-adc-skb105-from-the-nmpa</link>
<guid isPermaLink="true">https://6ix.com/company/sichuan-kelun-biotech/news/kelun-biotech-receives-investigational-new-drug-approval-for-itgb6-targeted-adc-skb105-from-the-nmpa</guid>
<pubDate>Mon, 05 Jan 2026 12:00:00 GMT</pubDate>
<description>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that its Investigational New Drug (IND) application for SKB105 (also known as CR-003), an internally developed integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the treatment of advanced solid tumors.</description>
</item>
<item>
<title>Kelun-Biotech Announces Breakthrough Therapy Designation Granted in China for Sacituzumab Tirumotecan (sac-TMT) in Combination with Immunotherapy Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC</title>
<link>https://6ix.com/company/sichuan-kelun-biotech/news/kelun-biotech-announces-breakthrough-therapy-designation-granted-in-china-for-sacituzumab-tirumotecan-sac-tmt-in-combination-with-immunotherapy-pembrolizumab-for-first-line-treatment-of-pd-l1-positive-nsclc</link>
<guid isPermaLink="true">https://6ix.com/company/sichuan-kelun-biotech/news/kelun-biotech-announces-breakthrough-therapy-designation-granted-in-china-for-sacituzumab-tirumotecan-sac-tmt-in-combination-with-immunotherapy-pembrolizumab-for-first-line-treatment-of-pd-l1-positive-nsclc</guid>
<pubDate>Mon, 05 Jan 2026 09:29:00 GMT</pubDate>
<description>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company," 6990.HK) today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®) in combination with MSD's anti-PD-1 monoclonal antibody pembrolizumab (KEYTRUDA®[1]) was granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the first-line treatm</description>
</item>
<item>
<title>Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics</title>
<link>https://6ix.com/company/sichuan-kelun-biotech/news/kelun-biotech-and-crescent-biopharma-announce-strategic-partnership-to-develop-and-commercialize-novel-oncology-therapeutics</link>
<guid isPermaLink="true">https://6ix.com/company/sichuan-kelun-biotech/news/kelun-biotech-and-crescent-biopharma-announce-strategic-partnership-to-develop-and-commercialize-novel-oncology-therapeutics</guid>
<pubDate>Thu, 04 Dec 2025 11:50:00 GMT</pubDate>
<description>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", 6990.HK), which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs, and Crescent Biopharma, Inc. ("Crescent") (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the companies have entered into a strategic partnership to develop and commercialize oncology thera</description>
</item>
<item>
<title>/C O R R E C T I O N -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd./</title>
<link>https://6ix.com/company/sichuan-kelun-biotech/news/c-o-r-r-e-c-t-i-o-n-sichuan-kelun-biotech-biopharmaceutical-co-ltd</link>
<guid isPermaLink="true">https://6ix.com/company/sichuan-kelun-biotech/news/c-o-r-r-e-c-t-i-o-n-sichuan-kelun-biotech-biopharmaceutical-co-ltd</guid>
<pubDate>Fri, 28 Nov 2025 05:13:00 GMT</pubDate>
<description>Recently, Clinical study results from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990)'s TROP2 ADC sacituzumab tirumotecan (sac-TMT) monotherapy for advanced or metastatic urothelial carcinoma (UC) patients has been published in the journal of Annals of Oncology (Impact Factor: 65.4). This study provides the first evidence of sac-TMT's potential significant clinical benefit for patients with advanced UC.</description>
</item>
<item>
<title>The Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma</title>
<link>https://6ix.com/company/sichuan-kelun-biotech/news/the-annals-of-oncology-publishes-results-of-phase-ii-study-of-sacituzumab-tirumotecan-monotherapy-for-urothelial-carcinoma</link>
<guid isPermaLink="true">https://6ix.com/company/sichuan-kelun-biotech/news/the-annals-of-oncology-publishes-results-of-phase-ii-study-of-sacituzumab-tirumotecan-monotherapy-for-urothelial-carcinoma</guid>
<pubDate>Fri, 28 Nov 2025 04:32:00 GMT</pubDate>
<description>Recently, Clinical study results from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990)'s TROP2 ADC sacituzumab tirumotecan (sac-TMT) monotherapy for advanced or metastatic urothelial carcinoma (UC) patients has been published in the journal of Annals of Oncology (Impact Factor: 65.4). This study provides the first evidence of sac-TMT's potential significant clinical benefit for patients with advanced UC.</description>
</item>
<item>
<title>Kelun-Biotech Announces Phase III Trial of Sac-TMT in Combination with KEYTRUDA® (pembrolizumab) as First-Line Treatment for PD-L1-Positive NSCLC Met Primary Endpoint</title>
<link>https://6ix.com/company/sichuan-kelun-biotech/news/kelun-biotech-announces-phase-iii-trial-of-sac-tmt-in-combination-with-keytrudar-pembrolizumab-as-first-line-treatment-for-pd-l1-positive-nsclc-met-primary-endpoint</link>
<guid isPermaLink="true">https://6ix.com/company/sichuan-kelun-biotech/news/kelun-biotech-announces-phase-iii-trial-of-sac-tmt-in-combination-with-keytrudar-pembrolizumab-as-first-line-treatment-for-pd-l1-positive-nsclc-met-primary-endpoint</guid>
<pubDate>Mon, 24 Nov 2025 12:00:00 GMT</pubDate>
<description>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded that the Phase III clinical study (OptiTROP-Lung05) of the company's TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870), in combination with MSD's anti-PD-1 therapy KEYTRUDA®[1] (pembrolizumab), as a first-line treatment for PD-L1-positive advanced non-small cell lung cancer (NSCLC), has demonstrated a statistically sign</description>
</item>
</channel>
</rss>